Regulatory
Nature Reviews Drug Discovery
Biotech news today
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Clinical N Nature Medicine
Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
Clinical N Nature Medicine
Author Correction: In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Industry
BioCentury
Astellas takes option on Audax’s IL-12 program: Deals Report
BIOCENTURY | DEALSASTELLAS TAKES OPTION ON AUDAX’S IL-12 PROGRAM: DEALS REPORTPlus: BioMarin looks to Korea to expand Fabry franchise; and more
Clinical
BioCentury
Missed endpoints, futility findings drive string of CNS discontinuations
BIOCENTURY | PRODUCT DEVELOPMENTMISSED ENDPOINTS, FUTILITY FINDINGS DRIVE STRING OF CNS DISCONTINUATIONSBioCentury’s Clinical Report Oct. 28–Nov. 2
Regulatory
Drug Discovery and Development
FDA approved Inovio’s Voceryq with open questions about its delivery device
The U.S. Food and Drug Administration has asked Inovio Pharmaceuticals, a company developing DNA-based medicines, to reanalyze its human factors testing of the Cellectra 5PSP, the electroporation device that delivers its newly approved drug Voceryq, and to verify the device’s sha…
Industry
BioCentury
Pharma’s U.S. contributions favor incumbents
BIOCENTURY | DATA BYTEPHARMA’S U.S. CONTRIBUTIONS FAVOR INCUMBENTSPharma PACs’ party split roughly tracks the balance of power in Congress
Software
BioCentury
Pharma a safe haven from an AI crash?
BIOCENTURY | DATA BYTEPHARMA A SAFE HAVEN FROM AN AI CRASH?Friday’s tech sell-off hints at a defensive role for large-cap biopharma, but not necessarily biotech more broadly
Regulatory
BioCentury
FDA commissioner: CEO or policy wonk?
BIOCENTURY | GUEST COMMENTARYFDA COMMISSIONER: CEO OR POLICY WONK?Washington asks what FDA nominees believe. It should ask whether they can run the agency, argues former FDA Senior Advisor Peter Reikes
Industry
Drug Discovery and Development
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Drug prices are one of the few issues on which Donald Trump has found common ground with progressive Democrats, and with voters in both parties. A March 2026 KFF poll found that 72% of adults say there is not enough government regulation limiting drug prices, including 77% of Dem…
Industry B BioPharm International
FAQ: What You Should Know About CAR-T Therapy in Solid and CNS Tumors
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Industry
BioCentury
Former CDER Director Tidmarsh says Prasad orchestrated ouster
BIOCENTURY | POLITICS, POLICY & LAWFORMER CDER DIRECTOR TIDMARSH SAYS PRASAD ORCHESTRATED OUSTERTidmarsh lawsuit illuminates in-fighting under Makary, accuses Kevin Tang and Aurinia Pharmaceuticals of defamation
Software B BioPharm International
AAPS PharmSci 360 2026: 5 Takeaways on AI, Oral Peptides, and Antibody Costs
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
Industry
Drug Discovery and Development
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Fresenius gets option rights on up to 37 first-to-market biosimilar candidates developed by WuXi Biologics, starting with copies of Roche's Polivy and Amgen's Tepezza. Fresenius picks the programs and keeps the economics; WuXi Biologics builds them for a per-program fee. The post…
Regulatory
MedCity News
Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor
Inovio’s Voceryq will compete with a Precigen product that last year became the first FDA-approved drug for recurrent respiratory papillomatosis, or RRP. While the two immunotherapies carry the same $460,000 list price, Inovio executives claim their product has another competitiv…
Industry
Inside Precision Medicine
Cervical Cancer Cases and Deaths Increasing, Particularly in Africa
Cervical cancer rates and deaths are increasing around the world, with the highest rates in developing countries and regions like sub-Saharan Africa. The post Cervical Cancer Cases and Deaths Increasing, Particularly in Africa appeared first on Inside Precision Medicine.
Clinical
Bio.News
PACE panel lays out patient input possibilities in PDUFA VIII
The law guiding U.S. drug approval was created to meet the demands of patient advocates, and the patient community still shapes the process. Stakeholders […] The post PACE panel lays out patient input possibilities in PDUFA VIII appeared first on Bio.News.
Regulatory P Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Voceryq
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
Agriculture
AgriBusiness Global
UPL Q2 and H1 FY27 Results: UPL Sustains Profitable Growth Amid Global Headwinds and Cost Inflation
UPL extends streak of margin growth as Advanta and specialty chemicals businesses drive performance. The post UPL Q2 and H1 FY27 Results: UPL Sustains Profitable Growth Amid Global Headwinds and Cost Inflation appeared first on AgriBusiness Global.
Regulatory
GEN
FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy
uniQure has aligned with the FDA on what the company calls key elements of the confirmatory study design: The study is being designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, wit…
Industry
Inside Precision Medicine
Cancer’s Genetic Weak Spot Offers New Route to Target WNT Signaling
Researchers at Weill Cornell Medicine have discovered a genetic vulnerability in cancer cells that could make it possible to block WNT signaling without damaging healthy tissue. The findings point to a more selective treatment strategy for colorectal, breast and other cancers. Th…
Manufacturing B BioProcess International
Grafting a solution: Rebuilding veins without risking rejection
Verigraft’s CEO spoke to BioProcess International about how advances in technology are poised to improve the quality of life for millions of patients with chronic vein diseases.
Industry B BioPharm International
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
Industry
GEN
Inflammatory Process Identified as Link Between Pulmonary Hypertension and Cognitive Decline
A study investigating the observed connection between pulmonary hypertension and cognitive decline symptoms has linked brain abnormalities in pulmonary hypertension to the same inflammatory processes that drive disease in the lungs and heart. The post Inflammatory Process Identif…
Industry
Inside Precision Medicine
Molecular Profiling May Help Predict Immunotherapy Outcomes in Small Cell Lung Cancer
A new study suggests that gene expression patterns and tumor immune characteristics could help identify patients with small cell lung cancer who are more likely to experience favorable outcomes following immunotherapy. The post Molecular Profiling May Help Predict Immunotherapy O…
Industry P Pharmaceutical Commerce
How an FTZ Builds More Flexibility Into Pharmaceutical Inventory Strategy
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Industry B BioPharm International
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
Software C Chan Zuckerberg Biohub
Biohub’s Residency Program: Pushing the Frontiers of Imaging, Together
Experts in advanced light microscopy, cryo-ET, computational imaging, and other measurement modalities collaborate with Biohub scientists to catalyze breakthroughs The post Biohub’s Residency Program: Pushing the Frontiers of Imaging, Together appeared first on Biohub.
Industry
European Biotechnology
Fresenius turns to WuXi to add up to 37 biosimilars to its pipeline
Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics approach the end of their patent protection and biosimilars could become an impo…
Industry
BioPharma Dive
Karyopharm, deep in debt, to sell itself in bankruptcy
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
Industry
STAT Biotech
STAT+: Psilocybin’s lasting benefits prove elusive in mice
Five Bay Area labs teamed up to compare lasting effects of psilocybin on anxiety and depression-like behavior in mice, with limited results:
Clinical
Pharmaceutical Processing World
AI in clinical trials: practical uses and limits
Indero's Guillaume Gigon on where AI helps clinical trials, from protocol drafting to data validation, and why data quality and oversight set its limits. The post AI in clinical trials: practical uses and limits appeared first on Pharmaceutical Processing World.
Industry
MedTech Dive
Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion
Abbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.
Industry
Pharmaceutical Technology
Fresenius and WuXi team up in 37-strong biosimilar development deal
The deal covers assets that target more than €370bn in originator sales.
Clinical A Applied Clinical Trials
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Software M Mac in Chem
A couple of interesting posts
I’m seeing an increasing number of useful utilities being developed using AI coding tools NISPO NISPO is an open-source, RDKit-based Python package for generating IUPAC
Industry
MedTech Dive
AdvaMed Chair Mick Farrell shares his top priorities, challenges for the medtech industry
In a year where companies are grappling with cyberattacks, inflation and potential tariffs, Farrell, who is also CEO of Resmed, shared a bird’s eye view of the issues.
Regulatory B BioPharm International
FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
Clinical
Clinical Trials Arena
Aer Therapeutics’ mucus-targeting drug fails Phase IIa COPD trial
The drug could also be used in indications including asthma and CF, but Aer Therapeutics has not confirmed whether it will continue its development. The post Aer Therapeutics’ mucus-targeting drug fails Phase IIa COPD trial appeared first on Clinical Trials Arena.
Industry P Pharmaceutical Executive
States Take Center Stage in the Drug Pricing Fight
PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.